2024
Real-world comparison of health care costs of venetoclax-obinutuzumab vs Bruton's tyrosine kinase inhibitor use among US Medicare beneficiaries with chronic lymphocytic leukemia in the frontline setting.
Huntington S, Manzoor B, Jawaid D, Puckett J, Emechebe N, Ravelo A, Kamal-Bahl S, Doshi J. Real-world comparison of health care costs of venetoclax-obinutuzumab vs Bruton's tyrosine kinase inhibitor use among US Medicare beneficiaries with chronic lymphocytic leukemia in the frontline setting. Journal Of Managed Care & Specialty Pharmacy 2024, 30: 1106-1116. PMID: 39046941, PMCID: PMC11424914, DOI: 10.18553/jmcp.2024.24049.Peer-Reviewed Original ResearchChronic lymphocytic leukemiaMonths 0Frontline settingSample of older US adultsMedicare beneficiariesLymphocytic leukemiaFee-for-service Medicare beneficiariesTreatment periodStudy of older adultsTyrosine kinase inhibitor useOlder US adultsBruton tyrosine kinase inhibitorFixed-duration therapyUS Medicare beneficiariesFee-for-serviceMonthly costTyrosine kinase inhibitorsHealth care costsMedicare Part ABcl-2 inhibitorsMultivariate general linear modelMonthly total costsTotal monthly costsPrescription drug costsComparison of health care costs
2023
Older patients with chronic myeloid leukemia face suboptimal molecular testing and tyrosine kinase inhibitor adherence
Shallis R, Wang R, Zeidan A, Huntington S, Neparidze N, Stempel J, Mendez L, Di M, Ma X, Podoltsev N. Older patients with chronic myeloid leukemia face suboptimal molecular testing and tyrosine kinase inhibitor adherence. Blood Advances 2023, 7: 3213-3224. PMID: 36939371, PMCID: PMC10338212, DOI: 10.1182/bloodadvances.2022009074.Peer-Reviewed Original ResearchConceptsChronic myeloid leukemiaTKI adherenceTKI initiationOlder patientsMyeloid leukemiaEnd Results-Medicare databaseTyrosine kinase inhibitor usePolymerase chain reaction testingQuantitative polymerase chain reaction testingOlder patient populationCare of patientsHealth care accessReal-world studyReal-world evidenceLow socioeconomic statusLow-income subsidyFirst yearInfluenza vaccinationInhibitor useWorse survivalTKI treatmentMultivariable analysisPatient populationOptimal monitoringCare access